Assessed for eligibility N = 15593

Slides:



Advertisements
Similar presentations
Randomized controlled trials
Advertisements

Cardiovascular outcome in patients with dysglycemia with daily supplementation of n-3 fatty acids 1 ORIGIN trial (Outcome Reduction with an Initial Glargine.
1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.
Biostatistics Biostatistics is statistics applied to biology Design of experiments The limitations when working with human subjects Non-normality.
Study design P.Olliaro Nov04. Study designs: observational vs. experimental studies What happened?  Case-control study What’s happening?  Cross-sectional.
Lessons Learned: Recruiting And Enrollment in CAM Trials Suzanna M. Zick ND MPH, Elena Gillespie, Keith Aaronson MD MS, Martin Stevens MD University of.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
#1 Study Population. #2 What Is The Study Population? (1) Subset of the general population determined by the eligibility criteria GENERAL POPULATION eligibility.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Feasibility of Text Messaging to Improve Oral Anti-Cancer Agent Adherence in Older Cancer Patients S. Spoelstra, PhD, RN 1 ; B. Given, PhD, RN, FAAN 1.
Date of download: 6/24/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Aripiprazole, an Antipsychotic With a Novel Mechanism.
Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Immunogenicity of 13-Valent Pneumococcal Conjugate.
The PRECIS-2 tool: Matching Intent with Methods David Hahn, MD, MS, WREN Director Department of Family Medicine & Community Health University.
Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):
1 Clinical Studies Section of Labeling Joseph Porres, M.D., Ph.D. Medical Officer Division of Dermatologic and Dental Drug Products FDA.
Copyright © 1998 American Medical Association. All rights reserved.
Copyright © 2003 American Medical Association. All rights reserved.
Supplemental Figure S1 (A) (B) Any Statin ↓Randomisation
Copyright © 2010 American Medical Association. All rights reserved.
a randomized controlled trial
Journal of Microbiology, Immunology and Infection
Copyright © 2015 by the American Osteopathic Association.
Participants 18year old+
The Diabetic Retinopathy Clinical Research Network
Online Supplemental Material
Georgia Immunization Rates
Alcohol, Other Drugs, and Health: Current Evidence
Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary.
Proportion of patients that met the SRI-5 response criteria (A and C) and reasons for non-response (B and D) in trial 1 (A and B) and trial 2 (C and D).
Alcohol, Other Drugs, and Health: Current Evidence
Comparison of the Effects of Pioglitazone versus Placebo when Given in Addition to Standard Insulin Treatment in Patients with Type 2 Diabetes Mellitus.
Copyright © 2013 American Medical Association. All rights reserved.
Copyright © 2002 American Medical Association. All rights reserved.
Martha Carvour, MD, PhD March 2, 2017
Copyright © 2004 American Medical Association. All rights reserved.
Copyright © 2000 American Medical Association. All rights reserved.
UOG Journal Club: January 2018
Assessed for eligibility (n = 38)
Volume 143, Issue 6, Pages (June 2013)
Copyright © 2013 American Medical Association. All rights reserved.
Assessed for eligibility (N = )
S1316 analysis details Garnet Anderson Katie Arnold
Cardiovascular outcomes
Community Health Indicators
Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease Martin et al. Am J Nephrol 2017;45: (DOI:
Personalized prevention: mobile application for smokers
Point-of-care C-reactive protein testing to reduce inappropriate use of antibiotics for non-severe acute respiratory infections in Vietnamese primary.
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS I)
Long-term Data: INPULSIS®-ON
Consolidated Standards of Reporting Trials (CONSORT) diagram of patients enrolled in the study. #: Two pre-screen/screen failures were erroneously randomised,
Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study
Accepted for analysis (n=232),
Volume 145, Issue 4, Pages e8 (October 2013)
Safety of Celecoxib in Patients With Ulcerative Colitis in Remission: A Randomized, Placebo-Controlled, Pilot Study  William J. Sandborn, William F. Stenson,
Supplemental Figure 1A Pt Pt Pre-treatment
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?  O.A. Cornely  Clinical Microbiology and.
Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial by Ersi Voskaridou,
Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis  Gary R. Lichtenstein,
Corticosteroids in the ICU
Volume 375, Issue 9719, Pages (March 2010)
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Assessed for eligibility (n=71)
Stavros V. Konstantinides et al. JACC 2017;69:
FIGURE 1. Flowchart of PnCRM7 clinical trial participants, primary efficacy cohort, and sub-populations used for efficacy analyses. Clinical trial participants.
Volume 128, Issue 4, Pages (April 2005)
Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised.
Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.
Enrolled and randomized Per-protocol efficacy population
Study design. aPatients initially receiving tenapanor 30 mg twice a day were allowed to down-titrate weekly (stepwise 30 → 20 → 15 → 10 → 3 mg twice a.
Presentation transcript:

Assessed for eligibility N = 15593 Figure 1. online only Trial profile Assessed for eligibility N = 15593 Eligible but not enrolled N = 993 Death before 6 weeks of age N = 154 Medical reasons N = 57 Non-user of health center N = 249 Refused N = 533 Not eligible N = 2406 Foreseen Migration N = 2292 Other * N = 114 Randomized N = 12194 Allocated to 11PCV n = 6098 - Received 1 dose 11PCV n = 6097 - Received 2 doses 11PCV n = 6054 - Received 3 doses 11PCV n = 6023 - Did not receive any dose n = 1 of 11PCV due to voluntary withdrawal Allocated to placebo n = 6096 - Received 1 dose placebo n = 6094 - Received 2 doses placebo n = 6052 - Received 3 doses placebo n = 6026 - Did not receive any dose of n = 2 placebo due to protocol violation Intent-to-treat Population n = 6097 Per Protocol Population n =6013 Excluded from analysis n = 84 -Incomplete number of doses n = 74 - Incorrect timing n = 4 - Incorrect treatment at any visit n = 3 -Vaccinated per protocol, n = 3 but exited during 14 days following the 3rd dose Intent-to-treat Population n = 6094 Per Protocol Population n = 6018 Excluded from analysis n = 76 - Incomplete number of doses n = 68 - Incorrect treatment at any visit n = 2 - Vaccinated per protocol n = 6 but exited during 14 days following the 3rd dose ** Other reasons for non-eligibility were: Already received DTP (N=22); Too old (11); Could not be identified (N=80);Ward of social service (1)